ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 127

Disease Characteristics and Outcomes in African-American Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis:  a High Risk Group for Poor Outcomes

Philip McCarthy1, Danielle Robson1, Jenna Hudy2, Marie Melville2, John McKinnon2, Sandeep Soman2 and Kathleen Maksimowicz-McKinnon3, 1Michigan State University College of Osteopathic Medicine, East Lansing, MI, 2Henry Ford Hospital, Detroit, MI, 3Rheumatology, Henry Ford Hospital, Detroit, MI

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: African-Americans, ANCA, outcomes and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Healthcare Disparities in Rheumatology - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Antineutrophil antibody-associated vasculitis (AAV) has been most extensively described and studied in non-African American populations. Little is known about the characteristics and outcomes of AAV in African American patients.

Methods: Retrospective chart review of patients self-identified as African-American with positive antineutrophil cytoplasmic antibody testing was performed. Records were reviewed in detail to establish disease classification of patients using the revised Chapel Hill 2012 AAV criteria.

Results: 21 patients with definite AAV were identified (10 GPA, 8 MPA, 3 with isolated renal AAV). Fourteen (66.7%) were female, with a mean age at symptom onset of 59 years. 4 patients (19%) were C-ANCA/PR-3 positive, all of whom had GPA. 100% of isolated renal AAV and 75% of MPA patients were P-ANCA/MPO positive. Nine patients (42.8%) were antinuclear antibody positive, and 5 patients (23.8%) had a positive rheumatoid factor. At the time of diagnosis for the 18 GPA and MPA patients, recurrent sinusitis was found in 12 patients (66.7%), but otalgia or otitis was less common, noted in only 4 patients (22.2%) Sixteen patients (88.9%) had pulmonary infiltrates, ten patients (55.6%) had diffuse alveolar hemorrhage, and 8 patients (44.4%) required mechanical ventilation at presentation. 11 patients (52.3%) of the entire cohort required hemodialysis at presentation, and 12 patients (57.1%) ultimately developed end stage renal disease (ESRD). Fourteen patients had concomitant hypertension, with a mean number of antihypertensive medications of 1.7. Seven patients had diabetes mellitus, with a mean glycated hemoglobin of 7.5 and mean duration of disease of 7.7 years. 9 patients (42.8%) developed at least one relapse, with a mean time to relapse of 20.5 months following diagnosis. Eight patients (38%) died, with a mean time to death from diagnosis of 32 months.

Conclusion: African-American patients with AAV frequently present with pulmonary and renal manifestations, which are often severe at onset, requiring supportive care. More than half of this cohort went on to develop ESRD, and over one-third died on average within 3 years following their diagnosis, demonstrating that AAV may have an aggressive course in these patients. There are many possible factors that could influence these outcomes, including other comorbid conditions, delay in diagnosis, genetics, environmental factors, and limited access to care. Further study is needed to better understand factors that influence AAV severity and course in this population in order to improve long-term outcomes and survival.


Disclosure: P. McCarthy, None; D. Robson, None; J. Hudy, None; M. Melville, None; J. McKinnon, None; S. Soman, None; K. Maksimowicz-McKinnon, None.

To cite this abstract in AMA style:

McCarthy P, Robson D, Hudy J, Melville M, McKinnon J, Soman S, Maksimowicz-McKinnon K. Disease Characteristics and Outcomes in African-American Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis:  a High Risk Group for Poor Outcomes [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/disease-characteristics-and-outcomes-in-african-american-patients-with-antineutrophil-cytoplasmic-antibody-associated-vasculitis-a-high-risk-group-for-poor-outcomes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-characteristics-and-outcomes-in-african-american-patients-with-antineutrophil-cytoplasmic-antibody-associated-vasculitis-a-high-risk-group-for-poor-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology